{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.2","upperLimit":"13.3","value":"10.9"},{"groupId":"OG001","lowerLimit":"7.2","upperLimit":"9.9","value":"8.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"OG000","title":"Nivolumab Arm"},{"description":"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends\n\nOR\n\nPaclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"OG001","title":"Active Comparator Arm （Docetaxel/Paclitaxel）"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"(\"Date of death from any cause\" - \"Date of randomization\" + 1) / 30.4375. For subjects lost to follow-up and subjects who are alive at the time of data cutoff date, data will be censored at the time the subject was last confirmed to be alive.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}